Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR for Irinotecan-Induced Diarrhea in Colorectal Cancer
NCT00006269Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 1999
- Primary completion
- Dec 1999
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diarrhea comparing Octreotide + Irinotecan with Placebo + Irinotecan (2 arms). Primary endpoint: Incidence of grade 2-4 diarrhea after completion of irinotecan. Started Dec 1999; status: terminated.
02
Drugs
octreotide
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT00006269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006269.